ClinicalTrials.gg
CompletedNCT04632706Updated Dec 27, 2021Results posted

Exploratory Ph I Trial of the Active IMP in Healthy Volunteers in Relation to COVID-19

A Phase 1 interventional study of Ivermectin and Placebo in Covid19, sponsored by MedinCell S.A. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-12-27.

Sponsored by MedinCell S.A · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 55 studies testing ivermectin in COVID-19 — 2 open to participants now, 2 under way, 1 of them phase 3. Ivermectin · COVID-19.

Enrollment
52nd of 55
24 · median 180
Started
2020
with 30 others
Phase 1
3 of 55
none open now
Registered
22nd of 55
by date
Lead sponsor
2 of 55
MedinCell S.A

Among the 55 studies testing ivermectin in COVID-19, this one is the 52nd largest by enrollment, is one of 31 that started in 2020, is one of 3 in phase 1, and was the 22nd registered.

COVID-19

7,994 studies on the registry are indexed under COVID-19; 468 are open to participants now.

Browse COVID-19 studies →

Open to participants now

2 of the 55 studies testing ivermectin in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About ivermectin

Ivermectin: first FDA approval 1996 (STROMECTOL). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.

This study: 18 Years to 45 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies testing ivermectin in COVID-19, or all of them as a file.
02

Study summary

An early stage trial to check how safe and tolerable, as well as how the body handles continuous daily use of Active IMP over 28 days in healthy volunteers.

Read the detailed description

Detailed information restricted because this is a Phase 1 clinical trial.

03

Conditions studied

  • Covid19

Browse trials for

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Eligibility criteria

Important Inclusion Criteria:

  • Subject is male of any ethnic origin.
  • Subject is aged between 18 to 45 years, inclusive.
  • Subject has a (BMI) of 18.5 to 32.0 kg/m2, inclusive.
  • Subject is ≥50 kg.
  • Negative reverse transcription polymerase chain reaction (RT-PCR) Test for severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) at Screening and negative lateral flow immunoassay test for SARS-CoV-2 at Day -1.
  • Healthy as determined by a responsible physician, based on medical evaluation including medical history, physical examinations, neurological examinations, concomitant medication, vital signs, 12-lead and clinical laboratory evaluations.
  • Male subjects must use a condom during the study and for 3 months after their final dose of study medication, if their partner is a woman of . In addition, their female partner of childbearing potential must use an additional method of highly effective from first dosing until 3 months following final dosing.

Important Exclusion Criteria:

  • history of abnormal physical or mental health (defined as any subject requiring medical, psychological or pharmacotherapeutic intervention for mental illness) interfering with the study as determined by medical history and physical examinations obtained during Screening and Day -1 as judged by the Investigator (including [but not limited to], neurological, psychiatric, endocrine, cardiovascular, respiratory, gastrointestinal, hepatic, or renal disorder).
  • Any other concomitant disease or condition that could interfere with, or for which the treatment might interfere with, the conduct of the study as outlined in this Protocol, or that would, in the opinion of the Investigator, pose an unacceptable risk to the subject in this study.
  • Evidence of previous SARS-CoV-2 infection from medical history.
  • Ophthalmologic disorder (moderate and sever retina or optic nerve pathology; cataracts excluded).
  • Subjects with a diagnosis of asthma or any other respiratory conditions.
  • A neurologic disorder that may compromise blood brain barrier permeability (stroke within 90 days, brain tumour, multiple sclerosis, or other neuroinflammatory condition, a neurodegenerative disorder, epilepsy) or history of seizures.
  • Positive test for surface antigen (HBsAg), anti- antibody (anti-HCV) or I and II (anti-HIV I/II) at Screening.
  • The subject has participated in a clinical study and has received a medication or a new chemical entity within 3 months or 5 half-lives (whichever is longer) prior to first dosing of current study medication.
  • Use of any drugs that are known substrates of , P-glycoprotein (P-gp) from within 4 weeks of Screening and unable to refrain from them until the end of the study (e.g., rifampicin, quinidine, amiodarone, diltiazem, spironolactone, verapamil, clarithromycin, erythromycin, itraconazole, ketoconazole, cyclosporine, tacrolimus, indinavir, ritonavir or cobicistat). Use of critical CYP3A4 substrate drugs such as warfarin or coumarin anticoagulants.
  • Recent or expected microfilaricidal drug use, including ivermectin, or travel history to areas that are endemic for Loa loa or onchocerciasis (Angola, Cameroon, Central African Republic, Chad, Democratic Republic of Congo, Ethiopia, Equatorial, Guinea, Gabon, Republic of Congo, Nigeria and Sudan).
  • Use of medications having potential activity against SARS-CoV-2 such as hydroxychloroquine, chloroquine, lopinavir, ritonavir, remdesivir, azithromycin, in the 30 days prior to Screening and unable to refrain from them until the end of the study.
  • Consumption of any food or drinks containing cranberry, pomegranate, starfruit, grapefruit, pomelos, exotic citrus fruits or Seville oranges (including marmalade and juices made from these fruits) within 14 days prior to first dosing until the end of the study.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Double (Participant, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    50mcg/kg (oral)

    Ivermectin loading dose of 200 mcg/kg followed by daily doses of 50mcg/kg from D2 to D28

    Drug: Ivermectin

  • Experimental
    75mcg/kg (oral)

    Ivermectin loading dose of 200 mcg/kg followed by daily doses of 75mcg/kg from D2 to D28

    Drug: Ivermectin

  • Experimental
    100mcg/kg (oral)

    Ivermectin loading dose of 200 mcg/kg followed by daily doses of 100mcg/kg from D2 to D28

    Drug: Ivermectin

  • Placebo comparator
    Matching Placebo (oral)

    Placebo using tablets identical to the Active IMP

    Drug: Placebo

Interventions

  • Ivermectin: Investigation of the safety, tolerability and the pharmacokinetic profile of the active IMP in an exploratory study

  • DrugPlacebo

    Matching Placebo to the Active IMP.

06

What researchers measure

Primary outcomes

  1. Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])

    Maximum plasma concentration (Cmax)

    Time frame: D1, D2 and D28

  2. Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])

    Time to reach Cmax (Tmax)

    Time frame: D1, D2 and D28

  3. Pharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr])

    area under the plasma concentration-time curve from zero to 24 hours (AUC0-24hr) concentration-time curve from zero to 24 hours (AUC0-24hr)

    Time frame: D1, D2 and D28

  4. Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])

    apparent terminal half-life (t1/2)

    Time frame: D28

Secondary outcomes

  1. Safety and Tolerability - Treatment Emergent Adverse Events (TEAEs)

    Clinical safety data from adverse event (AE) reporting

    Time frame: From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days.

07

Results

Posted Dec 27, 2021

Participant flow

Participant flow — Overall Study
Milestone50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)
Started6666
Completed6656
Not completed0010

Outcome measures

PrimaryPharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])

Maximum plasma concentration (Cmax)

Time frame:
D1, D2 and D28
Reported as:
Geometric mean · ng/mL
Pharmacokinetic Concentrations - (Maximum Plasma Concentration [Cmax])
ng/mL50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)
Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups57.2 ± 28.941.7 ± 73.546.5 ± 53.6
Day 2 (first day on respective dose of active treatment)22.3 ± 32.524.4 ± 42.533.2 ± 62.6
Day 28 (last day of active treatment)23.3 ± 52.831.9 ± 27.644.4 ± 68.8
Statistical analysis
  • 50mcg/kg (Oral) vs 75mcg/kg (Oral) vs 100mcg/kg (Oral) · Mixed Models Analysis · p = 0.803 (If the p-value is more than 0.05 then dose proportionality can not be confirmed.)
PrimaryPharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])

Time to reach Cmax (Tmax)

Time frame:
D1, D2 and D28
Reported as:
Geometric mean · hr
Pharmacokinetic Concentrations - (Time to Reach Cmax [Tmax])
hr50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)
Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups2.53 ± 36.83.03 ± 50.64.8 ± 47.2
Day 2 (first day on respective dose of active treatment)3.82 ± 36.72.85 ± 38.83.23 ± 34.5
Day 28 (last day of active treatment)2.83 ± 39.23.03 ± 50.73.03 ± 39.4
PrimaryPharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr])

area under the plasma concentration-time curve from zero to 24 hours (AUC0-24hr) concentration-time curve from zero to 24 hours (AUC0-24hr)

Time frame:
D1, D2 and D28
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetic Concentrations - (Area Under the Plasma Concentration-time Curve From Zero to 24 Hours [AUC0-24hr])
ng*h/mL50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)
Day 1 after loading dose of 200mcg/kg (oral) for all active treatment groups568 ± 33.6449 ± 62.0523 ± 60.5
Day 2 (first day on respective dose of active treatment)906 ± 31.4779 ± 53.1941 ± 59.0
Day 28 (last day of active treatment)1.06 ± 36.61.5 ± 47.51.75 ± 20.6
Statistical analysis
  • 50mcg/kg (Oral) vs 75mcg/kg (Oral) vs 100mcg/kg (Oral) · Mixed Models Analysis · p = 0.689 (If the p-value is more than 0.05 then dose proportionality can not be confirmed.)
PrimaryPharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])

apparent terminal half-life (t1/2)

Time frame:
D28
Reported as:
Geometric mean · hr
Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])
hr50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)
Pharmacokinetic Concentrations - (Apparent Terminal Half-Life [T1/2])102 ± 60.199.2 ± 47.3127 ± 47.2
SecondarySafety and Tolerability - Treatment Emergent Adverse Events (TEAEs)

Clinical safety data from adverse event (AE) reporting

Time frame:
From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days.
Reported as:
Number · TEAE
Safety and Tolerability - Treatment Emergent Adverse Events (TEAEs)
TEAE50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)
Any TEAE245221
Any serious TEAE0000
Any TEAE leading to discontinuation - due to Study Medication-related TEAE0000
Any TEAE leading to discontinuation - other reason0010
TEAE - mild severity245220
TEAE - moderate severity0001
Causality (All TEAEs) - Not related213220
Causality (All TEAEs) - Related (possibly and probably)3201

Adverse events

Collected over From Screening (Day -28) to Follow up visit (Day +42) plus 7 additional days. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
50mcg/kg (Oral)0/6 (0%)0/6 (0%)6/6 (100%)
75mcg/kg (Oral)0/6 (0%)0/6 (0%)3/6 (50%)
100mcg/kg (Oral)0/6 (0%)0/6 (0%)2/6 (33.3%)
Matching Placebo (Oral)0/6 (0%)0/6 (0%)6/6 (100%)
Ivermectin Overall0/18 (0%)0/18 (0%)11/18 (61.1%)
Total (Ivermectin Overall and Placebo)0/24 (0%)0/24 (0%)17/24 (70.8%)
Most frequent other events
Showing 10 of 30
Most frequent other events
Event50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Ivermectin OverallTotal (Ivermectin Overall and Placebo)
NauseaGastrointestinal disorders3/60/60/61/63/184/24
HeadacheNervous system disorders3/60/61/61/64/185/24
LethargyNervous system disorders1/60/60/62/61/183/24
SomnolenceNervous system disorders2/60/60/60/62/182/24
EpistaxisRespiratory, thoracic and mediastinal disorders0/60/60/62/60/182/24
Oropharyngeal painRespiratory, thoracic and mediastinal disorders2/60/60/60/62/182/24
PalpitationsCardiac disorders1/61/60/60/62/182/24
DiarrhoeaGastrointestinal disorders1/60/60/60/61/181/24
ToothacheGastrointestinal disorders0/60/60/61/60/181/24
Chest discomfortGeneral disorders0/60/60/61/60/181/24

Baseline characteristics

Age, Continuous
Age, Continuous(years)50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Total
Mean35.2 (25 to 45)29.3 (21 to 43)30.3 (21 to 43)28.2 (23 to 35)30.8 (21 to 45)
Sex: Female, Male
Sex: Female, Male(Participants)50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Total
Female00000
Male666624
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Total
Count of participants————0
Region of Enrollment
Region of Enrollment(participants)50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Total
United Kingdom666624
Body Mass Index
Body Mass Index(kg/m^2)50mcg/kg (Oral)75mcg/kg (Oral)100mcg/kg (Oral)Matching Placebo (Oral)Total
Mean24.95 (19.43 to 30.85)25.79 (21.73 to 29.24)25.84 (20.04 to 31.65)25.57 (23.57 to 29.10)25.54 (19.43 to 31.65)
08

Study locations

1 site
  • MAC Clinical Research Manchester (Early Phase Unit), Neuroscience Centre of Excellence
    Manchester, Greater Mancherster M13 9NQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2020 to primary completion in Mar 2021, 5 months.

Results were first posted in Dec 2021, 9 months after primary completion.

Of 233 industry-sponsored phase 1 interventional studies under COVID-19, half reached primary completion within 6 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 12. This study's 5 months is below that.

Counting every sponsor, half of 384 studies reached it within 7 months; a quarter within 3 and three quarters within 15.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 26, 2020
First posted
Nov 17, 2020
StartActual
Sep 22, 2020
Primary completionActual
Mar 9, 2021
CompletionActual
Mar 9, 2021
Results first posted
Dec 27, 2021
Last update
Dec 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04632706
Lead sponsor
MedinCell S.A
Responsible party
Sponsor
First posted
Nov 17, 2020
Start date
Sep 22, 2020
Primary completion
Mar 9, 2021
Completion
Mar 9, 2021
Results posted
Dec 27, 2021
Last update
Dec 27, 2021

Study contacts

Pui Man Leung, MD
principal investigator · MAC Clinical Research

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ivermectin

Start the discussion